首页 > 最新文献

Nature Reviews Gastroenterology &Hepatology最新文献

英文 中文
Intermittent fasting for NASH and HCC in mice 间歇性禁食治疗小鼠 NASH 和 HCC
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-14 DOI: 10.1038/s41575-024-00953-w
Jordan Hindson
{"title":"Intermittent fasting for NASH and HCC in mice","authors":"Jordan Hindson","doi":"10.1038/s41575-024-00953-w","DOIUrl":"10.1038/s41575-024-00953-w","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 7","pages":"461-461"},"PeriodicalIF":45.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the promise of RAS inhibition in pancreatic cancer 揭开 RAS 抑制剂在胰腺癌中的应用前景
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-14 DOI: 10.1038/s41575-024-00951-y
Saurav D. Haldar, Nilofer S. Azad
The advent of next-generation RAS inhibitors brings renewed optimism to the care of patients with pancreatic cancer after decades of failure for novel therapeutics. A recent study highlights the potent antitumour activity of the multi-selective RAS(ON) inhibitor RMC-7977 across a spectrum of preclinical pancreatic cancer models.
在新型疗法失败数十年之后,新一代 RAS 抑制剂的出现为胰腺癌患者的治疗带来了新的希望。最近的一项研究强调了多选择性RAS(ON)抑制剂RMC-7977在一系列临床前胰腺癌模型中的强大抗肿瘤活性。
{"title":"Unlocking the promise of RAS inhibition in pancreatic cancer","authors":"Saurav D. Haldar, Nilofer S. Azad","doi":"10.1038/s41575-024-00951-y","DOIUrl":"10.1038/s41575-024-00951-y","url":null,"abstract":"The advent of next-generation RAS inhibitors brings renewed optimism to the care of patients with pancreatic cancer after decades of failure for novel therapeutics. A recent study highlights the potent antitumour activity of the multi-selective RAS(ON) inhibitor RMC-7977 across a spectrum of preclinical pancreatic cancer models.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 8","pages":"535-536"},"PeriodicalIF":45.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease 开辟临床试验设计新途径,应对酒精使用障碍和酒精相关肝病
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-07 DOI: 10.1038/s41575-024-00948-7
Juliana Serrazina, Helena Cortez-Pinto
An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical trials, despite alcohol abuse and alcohol-related liver disease being one of the greatest causes of morbidity and mortality worldwide.
一个专家小组为酒精使用障碍和酒精相关肝病临床试验的设计和实施提出了 28 项建议。尽管酗酒和酒精相关肝病是全球发病率和死亡率最高的原因之一,但这一领域的临床试验却十分匮乏。
{"title":"Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease","authors":"Juliana Serrazina, Helena Cortez-Pinto","doi":"10.1038/s41575-024-00948-7","DOIUrl":"10.1038/s41575-024-00948-7","url":null,"abstract":"An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical trials, despite alcohol abuse and alcohol-related liver disease being one of the greatest causes of morbidity and mortality worldwide.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 9","pages":"607-608"},"PeriodicalIF":45.9,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement 设计针对饮酒和酒精相关肝病的临床试验:专家小组共识声明
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-07 DOI: 10.1038/s41575-024-00936-x
Brian P. Lee, Katie Witkiewitz, Jessica Mellinger, Frank A. Anania, Ramon Bataller, Thomas G. Cotter, Brenda Curtis, Srinivasan Dasarathy, Kelly S. DeMartini, Ivan Diamond, Nancy Diazgranados, Andrea F. DiMartini, Daniel E. Falk, Anne C. Fernandez, Margarita N. German, Patrick S. Kamath, Kelley M. Kidwell, Lorenzo Leggio, Raye Litten, Alexandre Louvet, Michael R. Lucey, Mary E. McCaul, Arun J. Sanyal, Ashwani K. Singal, Norman L. Sussman, Norah A. Terrault, Mark R. Thursz, Elizabeth C. Verna, Svetlana Radaeva, Laura E. Nagy, Mack C. Mitchell
Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined as 4 or more drinks per day (56 g) or 8 (112 g) or more drinks per week for women and 5 or more drinks per day (70 g) or 15 (210 g) or more drinks per week for men. Although abstinence from alcohol after diagnosis of ALD improves life expectancy and reduces the risk of decompensation of liver disease, few studies have evaluated whether treatment of alcohol use disorders will reduce progression of liver disease and improve liver-related outcomes. In November 2021, the National Institute of Alcohol Abuse and Alcoholism commissioned a task force that included hepatologists, addiction medicine specialists, statisticians, clinical trialists and members of regulatory agencies to develop recommendations for the design and conduct of clinical trials to evaluate the effect of alcohol use, particularly treatment to reduce or eliminate alcohol use in patients with ALD. The task force conducted extensive reviews of relevant literature on alcohol use disorders and ALD. Findings were presented at one in-person meeting and discussed over the next 16 months to develop the final recommendations. As few clinical trials directly address this topic, the 28 recommendations approved by all members of the task force represent a consensus of expert opinions. Alcohol-associated liver disease is the main cause of liver-related morbidity and mortality globally. This Consensus Statement makes recommendations for the design, best practice and conduct of clinical trials to evaluate the effects of alcohol use in alcohol-associated liver disease and alcohol use disorder.
大多数酒精相关性肝病(ALD)患者都有大量饮酒的习惯,女性指每天饮酒 4 杯(56 克)或每周饮酒 8 杯(112 克)或以上,男性指每天饮酒 5 杯(70 克)或每周饮酒 15 杯(210 克)或以上。虽然确诊 ALD 后戒酒可改善预期寿命并降低肝病失代偿的风险,但很少有研究评估治疗酒精使用障碍是否会减少肝病进展并改善肝脏相关预后。2021 年 11 月,美国国家酒精滥用和酒精中毒研究所委托一个包括肝病专家、成瘾医学专家、统计学家、临床试验专家和监管机构成员在内的特别工作组,为设计和开展临床试验制定建议,以评估酒精使用的影响,特别是减少或消除 ALD 患者酒精使用的治疗。特别工作组对酒精使用障碍和 ALD 的相关文献进行了广泛的审查。在一次面对面的会议上介绍了研究结果,并在接下来的 16 个月中进行了讨论,以制定最终建议。由于很少有临床试验直接涉及这一主题,因此工作组全体成员批准的 28 项建议代表了专家的一致意见。
{"title":"Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement","authors":"Brian P. Lee, Katie Witkiewitz, Jessica Mellinger, Frank A. Anania, Ramon Bataller, Thomas G. Cotter, Brenda Curtis, Srinivasan Dasarathy, Kelly S. DeMartini, Ivan Diamond, Nancy Diazgranados, Andrea F. DiMartini, Daniel E. Falk, Anne C. Fernandez, Margarita N. German, Patrick S. Kamath, Kelley M. Kidwell, Lorenzo Leggio, Raye Litten, Alexandre Louvet, Michael R. Lucey, Mary E. McCaul, Arun J. Sanyal, Ashwani K. Singal, Norman L. Sussman, Norah A. Terrault, Mark R. Thursz, Elizabeth C. Verna, Svetlana Radaeva, Laura E. Nagy, Mack C. Mitchell","doi":"10.1038/s41575-024-00936-x","DOIUrl":"10.1038/s41575-024-00936-x","url":null,"abstract":"Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined as 4 or more drinks per day (56 g) or 8 (112 g) or more drinks per week for women and 5 or more drinks per day (70 g) or 15 (210 g) or more drinks per week for men. Although abstinence from alcohol after diagnosis of ALD improves life expectancy and reduces the risk of decompensation of liver disease, few studies have evaluated whether treatment of alcohol use disorders will reduce progression of liver disease and improve liver-related outcomes. In November 2021, the National Institute of Alcohol Abuse and Alcoholism commissioned a task force that included hepatologists, addiction medicine specialists, statisticians, clinical trialists and members of regulatory agencies to develop recommendations for the design and conduct of clinical trials to evaluate the effect of alcohol use, particularly treatment to reduce or eliminate alcohol use in patients with ALD. The task force conducted extensive reviews of relevant literature on alcohol use disorders and ALD. Findings were presented at one in-person meeting and discussed over the next 16 months to develop the final recommendations. As few clinical trials directly address this topic, the 28 recommendations approved by all members of the task force represent a consensus of expert opinions. Alcohol-associated liver disease is the main cause of liver-related morbidity and mortality globally. This Consensus Statement makes recommendations for the design, best practice and conduct of clinical trials to evaluate the effects of alcohol use in alcohol-associated liver disease and alcohol use disorder.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 9","pages":"626-645"},"PeriodicalIF":45.9,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00936-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Envisioning how to advance the MASH field 设想如何推动 MASH 领域的发展
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-04 DOI: 10.1038/s41575-024-00938-9
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, Michael R. Charlton, Jeffrey V. Lazarus
Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced the prerequisites to address metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic non-communicable liver disease. This effort has led to, among others, the approval of the first drug specific for metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis). Despite substantial progress, MASLD is still a leading cause of advanced chronic liver disease, including primary liver cancer. This Perspective contextualizes the nomenclature change from nonalcoholic fatty liver disease to MASLD and proposes important considerations to accelerate further progress in the field, optimize patient-centric multidisciplinary care pathways, advance pharmacological, behavioural and diagnostic research, and address health disparities. Key regulatory and other steps necessary to optimize the approval and access to upcoming additional pharmacological therapeutic agents for MASH are also outlined. We conclude by calling for increased education and awareness, enhanced health system preparedness, and concerted action by policy-makers to further the public health and policy agenda to achieve at least parity with other non-communicable diseases and to aid in growing the community of practice to reduce the human and economic burden and end the public health threat of MASLD and MASH by 2030. This Perspective discusses the nomenclature change from nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) and proposes steps necessary to improve care and end the public health threat posed by MASLD and metabolic dysfunction-associated steatohepatitis.
自 1980 年以来,科学家和医疗保健领域的相关人士不断努力,为解决代谢功能障碍相关性脂肪性肝病(MASLD)这一普遍存在的慢性非传染性肝病提供了先决条件。这项工作的成果之一是批准了第一种治疗代谢功能障碍相关性脂肪性肝炎(MASH,以前称为非酒精性脂肪性肝炎)的特效药。尽管取得了重大进展,但代谢紊乱性脂肪性肝炎仍是导致晚期慢性肝病(包括原发性肝癌)的主要原因。本视角介绍了将非酒精性脂肪肝更名为 MASLD 的背景,并提出了一些重要的考虑因素,以加快该领域的进一步进展,优化以患者为中心的多学科护理途径,推进药物、行为和诊断研究,并解决健康差异问题。此外,我们还概述了为优化即将批准和使用的其他 MASH 药物治疗所需的关键监管和其他步骤。最后,我们呼吁加强教育和宣传,增强卫生系统的准备工作,并呼吁决策者采取一致行动,推进公共卫生和政策议程,至少实现与其他非传染性疾病的平等,并帮助扩大实践社区,以减轻人力和经济负担,到 2030 年消除 MASLD 和 MASH 对公共卫生的威胁。
{"title":"Envisioning how to advance the MASH field","authors":"Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, Michael R. Charlton, Jeffrey V. Lazarus","doi":"10.1038/s41575-024-00938-9","DOIUrl":"10.1038/s41575-024-00938-9","url":null,"abstract":"Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced the prerequisites to address metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic non-communicable liver disease. This effort has led to, among others, the approval of the first drug specific for metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis). Despite substantial progress, MASLD is still a leading cause of advanced chronic liver disease, including primary liver cancer. This Perspective contextualizes the nomenclature change from nonalcoholic fatty liver disease to MASLD and proposes important considerations to accelerate further progress in the field, optimize patient-centric multidisciplinary care pathways, advance pharmacological, behavioural and diagnostic research, and address health disparities. Key regulatory and other steps necessary to optimize the approval and access to upcoming additional pharmacological therapeutic agents for MASH are also outlined. We conclude by calling for increased education and awareness, enhanced health system preparedness, and concerted action by policy-makers to further the public health and policy agenda to achieve at least parity with other non-communicable diseases and to aid in growing the community of practice to reduce the human and economic burden and end the public health threat of MASLD and MASH by 2030. This Perspective discusses the nomenclature change from nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) and proposes steps necessary to improve care and end the public health threat posed by MASLD and metabolic dysfunction-associated steatohepatitis.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 10","pages":"726-738"},"PeriodicalIF":45.9,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hybrid APASL meeting 2024 2024 年亚太空间法中心混合会议
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-03 DOI: 10.1038/s41575-024-00949-6
Eleni Kotsiliti
{"title":"Hybrid APASL meeting 2024","authors":"Eleni Kotsiliti","doi":"10.1038/s41575-024-00949-6","DOIUrl":"10.1038/s41575-024-00949-6","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 7","pages":"461-461"},"PeriodicalIF":45.9,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endogenous ethanol production in health and disease 健康和疾病中的内源性乙醇生成。
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-03 DOI: 10.1038/s41575-024-00937-w
Abraham S. Meijnikman, Max Nieuwdorp, Bernd Schnabl
The gut microbiome exerts metabolic actions on distal tissues and organs outside the intestine, partly through microbial metabolites that diffuse into the circulation. The disruption of gut homeostasis results in changes to microbial metabolites, and more than half of the variance in the plasma metabolome can be explained by the gut microbiome. Ethanol is a major microbial metabolite that is produced in the intestine of nearly all individuals; however, elevated ethanol production is associated with pathological conditions such as metabolic dysfunction-associated steatotic liver disease and auto-brewery syndrome, in which the liver’s capacity to metabolize ethanol is surpassed. In this Review, we describe the mechanisms underlying excessive ethanol production in the gut and the role of ethanol catabolism in mediating pathogenic effects of ethanol on the liver and host metabolism. We conclude by discussing approaches to target excessive ethanol production by gut bacteria. Ethanol is produced in the gut by several different species of fermentative bacteria. This Review discusses the sources and consequences of endogenously produced ethanol, explores its relationship with liver diseases such as metabolic dysfunction-associated steatotic liver disease and covers approaches to target excessive ethanol production in the gut.
肠道微生物组对肠道外的远端组织和器官产生代谢作用,部分是通过扩散到血液循环中的微生物代谢物实现的。肠道平衡的破坏会导致微生物代谢物的变化,血浆代谢组中一半以上的差异可由肠道微生物组来解释。乙醇是一种主要的微生物代谢物,几乎所有个体的肠道中都会产生乙醇;然而,乙醇生成的增加与代谢功能障碍相关性脂肪肝和自酿综合征等病理状况有关,在这些病理状况中,肝脏代谢乙醇的能力被超越。在本综述中,我们阐述了肠道中乙醇产生过多的内在机制,以及乙醇分解在介导乙醇对肝脏和宿主新陈代谢的致病作用方面所起的作用。最后,我们将讨论针对肠道细菌产生过量乙醇的方法。
{"title":"Endogenous ethanol production in health and disease","authors":"Abraham S. Meijnikman, Max Nieuwdorp, Bernd Schnabl","doi":"10.1038/s41575-024-00937-w","DOIUrl":"10.1038/s41575-024-00937-w","url":null,"abstract":"The gut microbiome exerts metabolic actions on distal tissues and organs outside the intestine, partly through microbial metabolites that diffuse into the circulation. The disruption of gut homeostasis results in changes to microbial metabolites, and more than half of the variance in the plasma metabolome can be explained by the gut microbiome. Ethanol is a major microbial metabolite that is produced in the intestine of nearly all individuals; however, elevated ethanol production is associated with pathological conditions such as metabolic dysfunction-associated steatotic liver disease and auto-brewery syndrome, in which the liver’s capacity to metabolize ethanol is surpassed. In this Review, we describe the mechanisms underlying excessive ethanol production in the gut and the role of ethanol catabolism in mediating pathogenic effects of ethanol on the liver and host metabolism. We conclude by discussing approaches to target excessive ethanol production by gut bacteria. Ethanol is produced in the gut by several different species of fermentative bacteria. This Review discusses the sources and consequences of endogenously produced ethanol, explores its relationship with liver diseases such as metabolic dysfunction-associated steatotic liver disease and covers approaches to target excessive ethanol production in the gut.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 8","pages":"556-571"},"PeriodicalIF":45.9,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice 关于临床实践中纤维狭窄性小肠克罗恩病的定义、诊断和管理的全球共识
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-03 DOI: 10.1038/s41575-024-00935-y
Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rogler, Ren Mao, Jordi Rimola, William J. Sandborn, Siew C. Ng, Britta Siegmund, Mark Silverberg, Stuart A. Taylor, Bram Verstockt, Ilyssa O. Gordon, David H. Bruining, Brian G. Feagan, Florian Rieder, Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium
Fibrostenosis of the small bowel is common in patients with Crohn’s disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement, we present a clinical practice RAND/UCLA appropriateness study on the definition, diagnosis and clinical management of fibrostenosing Crohn’s disease. It was conducted by a panel of 28 global experts and one patient representative. Following a systematic literature review, 526 candidate items grouped into 136 questions were generated and subsequently evaluated for appropriateness. Strictures are best defined as wall thickening, luminal narrowing and prestenotic dilation. Cross-sectional imaging is required for accurate diagnosis of fibrostenosing Crohn’s disease, and it is recommended before making treatment decisions. It should also assess the degree of inflammation in the bowel wall. Multiple options for medical anti-inflammatory, endoscopic and surgical therapies were suggested, including follow-up strategies following therapy. This Consensus Statement supports clinical practice through providing guidance on definitions, diagnosis and therapeutic management of patients with fibrostenosing small bowel Crohn’s disease. In this Consensus Statement, a global multidisciplinary panel of experts provides recommendations for the definitions, diagnosis and management of patients with fibrostenosing small bowel Crohn’s disease.
小肠纤维狭窄在克罗恩病患者中很常见。目前还没有关于定义、诊断和临床实践管理的共识建议。在本共识声明中,我们介绍了兰德大学/加州大学洛杉矶分校关于纤维狭窄性克罗恩病的定义、诊断和临床管理的临床实践适宜性研究。该研究由 28 位全球专家和一位患者代表组成的小组进行。在系统性文献回顾之后,产生了 526 个候选项目,并将其分为 136 个问题,随后对其适当性进行了评估。狭窄的最佳定义是管壁增厚、管腔狭窄和狭窄前扩张。要准确诊断纤维狭窄性克罗恩病,需要进行横断面成像,建议在做出治疗决定前进行横断面成像。还应该评估肠壁的炎症程度。建议采用药物抗炎、内窥镜和手术疗法等多种方案,包括治疗后的随访策略。本共识声明为纤维增生性小肠克罗恩病患者的定义、诊断和治疗管理提供指导,从而为临床实践提供支持。
{"title":"A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice","authors":"Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rogler, Ren Mao, Jordi Rimola, William J. Sandborn, Siew C. Ng, Britta Siegmund, Mark Silverberg, Stuart A. Taylor, Bram Verstockt, Ilyssa O. Gordon, David H. Bruining, Brian G. Feagan, Florian Rieder, Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium","doi":"10.1038/s41575-024-00935-y","DOIUrl":"10.1038/s41575-024-00935-y","url":null,"abstract":"Fibrostenosis of the small bowel is common in patients with Crohn’s disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement, we present a clinical practice RAND/UCLA appropriateness study on the definition, diagnosis and clinical management of fibrostenosing Crohn’s disease. It was conducted by a panel of 28 global experts and one patient representative. Following a systematic literature review, 526 candidate items grouped into 136 questions were generated and subsequently evaluated for appropriateness. Strictures are best defined as wall thickening, luminal narrowing and prestenotic dilation. Cross-sectional imaging is required for accurate diagnosis of fibrostenosing Crohn’s disease, and it is recommended before making treatment decisions. It should also assess the degree of inflammation in the bowel wall. Multiple options for medical anti-inflammatory, endoscopic and surgical therapies were suggested, including follow-up strategies following therapy. This Consensus Statement supports clinical practice through providing guidance on definitions, diagnosis and therapeutic management of patients with fibrostenosing small bowel Crohn’s disease. In this Consensus Statement, a global multidisciplinary panel of experts provides recommendations for the definitions, diagnosis and management of patients with fibrostenosing small bowel Crohn’s disease.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 8","pages":"572-584"},"PeriodicalIF":45.9,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00935-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141235932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pride in gastroenterology and hepatology 以肠胃病学和肝病学为荣
IF 65.1 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-31 DOI: 10.1038/s41575-024-00939-8
For Pride Month, we celebrate the LGBTQ+ community and take stock of the challenges they continue to experience. Gastroenterologists and hepatologists can and should advocate, improve inclusion and be effective allies for our LGBTQ+ colleagues and patients.
在自豪月,我们庆祝 LGBTQ+ 群体,并总结他们继续经历的挑战。肠胃病学家和肝病学家可以而且应该为我们的 LGBTQ+ 同事和患者进行宣传、提高包容性并成为他们的有效盟友。
{"title":"Pride in gastroenterology and hepatology","authors":"","doi":"10.1038/s41575-024-00939-8","DOIUrl":"10.1038/s41575-024-00939-8","url":null,"abstract":"For Pride Month, we celebrate the LGBTQ+ community and take stock of the challenges they continue to experience. Gastroenterologists and hepatologists can and should advocate, improve inclusion and be effective allies for our LGBTQ+ colleagues and patients.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 6","pages":"367-367"},"PeriodicalIF":65.1,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00939-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of metastatic colorectal cancer 转移性结直肠癌的发病机制。
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-28 DOI: 10.1038/s41575-024-00934-z
Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle
Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited therapeutic options and a poor prognosis. This Review addresses the emerging focus on metastatic CRC (mCRC), which has historically been under-studied compared with primary CRC despite its lethality. We delve into two crucial aspects: the molecular and cellular determinants facilitating CRC metastasis and the principles guiding the evolution of metastatic disease. Initially, we examine the genetic alterations integral to CRC metastasis, connecting them to clinically marked characteristics of advanced CRC. Subsequently, we scrutinize the role of cellular heterogeneity and plasticity in metastatic spread and therapy resistance. Finally, we explore how the tumour microenvironment influences metastatic disease, emphasizing the effect of stromal gene programmes and the immune context. The ongoing research in these fields holds immense importance, as its future implications are projected to revolutionize the treatment of patients with mCRC, hopefully offering a promising outlook for their survival. Metastatic colorectal cancer (mCRC) has a poor prognosis, and therapeutic options are limited. This Review provides a comprehensive overview of the genetic and molecular underpinnings of mCRC, discussing the therapeutic potential arising from this knowledge.
尽管对结直肠癌(CRC)进行了广泛的研究,对其认识也有所提高,但其转移形式仍然是一个巨大的挑战,主要原因是治疗方案有限且预后较差。与原发性 CRC 相比,尽管转移性 CRC 具有致命性,但对它的研究历来不足。我们将深入探讨两个关键方面:促进 CRC 转移的分子和细胞决定因素以及指导转移性疾病演变的原则。首先,我们研究了 CRC 转移不可或缺的基因改变,并将其与晚期 CRC 的临床特征联系起来。随后,我们仔细研究了细胞异质性和可塑性在转移扩散和耐药性中的作用。最后,我们探讨了肿瘤微环境如何影响转移性疾病,强调了基质基因计划和免疫环境的影响。这些领域正在进行的研究具有极其重要的意义,因为其未来的影响预计将彻底改变 mCRC 患者的治疗方法,有望为他们的生存带来光明前景。
{"title":"Mechanisms of metastatic colorectal cancer","authors":"Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle","doi":"10.1038/s41575-024-00934-z","DOIUrl":"10.1038/s41575-024-00934-z","url":null,"abstract":"Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited therapeutic options and a poor prognosis. This Review addresses the emerging focus on metastatic CRC (mCRC), which has historically been under-studied compared with primary CRC despite its lethality. We delve into two crucial aspects: the molecular and cellular determinants facilitating CRC metastasis and the principles guiding the evolution of metastatic disease. Initially, we examine the genetic alterations integral to CRC metastasis, connecting them to clinically marked characteristics of advanced CRC. Subsequently, we scrutinize the role of cellular heterogeneity and plasticity in metastatic spread and therapy resistance. Finally, we explore how the tumour microenvironment influences metastatic disease, emphasizing the effect of stromal gene programmes and the immune context. The ongoing research in these fields holds immense importance, as its future implications are projected to revolutionize the treatment of patients with mCRC, hopefully offering a promising outlook for their survival. Metastatic colorectal cancer (mCRC) has a poor prognosis, and therapeutic options are limited. This Review provides a comprehensive overview of the genetic and molecular underpinnings of mCRC, discussing the therapeutic potential arising from this knowledge.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 9","pages":"609-625"},"PeriodicalIF":45.9,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nature Reviews Gastroenterology &Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1